Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Sanofi sees US FDA ruling for MS drug Lemtrada in Q4
Stress and hypothalamic-pituitary-adrenal axis function in experimental autoimmune encephalomyelitis and multiple sclerosis - a review.
Neuromyelitis optica.
Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis.
Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis.
Treatment selection and experience in multiple sclerosis: survey of neurologists.
Medical marijuana: clearing away the smoke.
Ultrasound aspects in therapy-naive CIDP compared to long-term treated CIDP.
UW-SES: A new self-efficacy scale for people with disabilities.
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)
Benign Multiple Sclerosis: Does it exist?
Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis.
Amiloride HCI Tablets, USP 5 mg
Immunology 2012
"Tell me what you want, what you really really want….": asking people with multiple sclerosis about enhancing their participation in physical activity.
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
The effects of intrathecal rituximab on biomarkers in multiple sclerosis.
Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease.
HERV-W envelope protein inhibits oligodendroglial precursor cell differentiation.
Natural History of Multiple Sclerosis Symptoms
Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome.
Celiac disease and multiple sclerosis in the northwest of Iran.
Inhibition of Neuronal Degenerin/Epithelial Na+ Channels by the Multiple Sclerosis Drug 4-Aminopyridine.
Memory rehabilitation for people with multiple sclerosis.
A major histocompatibility Class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01.

Pages